These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6746105)

  • 1. Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.
    Savoca KV; Davis FF; Palczuk NC
    Int Arch Allergy Appl Immunol; 1984; 75(1):58-67. PubMed ID: 6746105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase.
    Tsuji J; Hirose K; Kasahara E; Naitoh M; Yamamoto I
    Int J Immunopharmacol; 1985; 7(5):725-30. PubMed ID: 2412977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
    Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
    Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity.
    Nishimura H; Matsushima A; Inada Y
    Enzyme; 1981; 26(1):49-53. PubMed ID: 7194181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological properties of uricase conjugated to neutral soluble polymers.
    Caliceti P; Schiavon O; Veronese FM
    Bioconjug Chem; 2001; 12(4):515-22. PubMed ID: 11459455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase.
    Zhang C; Fan K; Ma X; Wei D
    PLoS One; 2012; 7(6):e39659. PubMed ID: 22745806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes.
    Nishida Y; Kamatani N; Miyamoto T
    J Pharm Pharmacol; 1984 May; 36(5):354-5. PubMed ID: 6145782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum.
    Nishimura H; Ashihara Y; Matsushima A; Inada Y
    Enzyme; 1979; 24(4):261-4. PubMed ID: 573687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification with polysialic acid-PEG copolymer as a new method for improving the therapeutic efficacy of proteins.
    Wu J; Lu S; Zheng Z; Zhu L; Zhan X
    Prep Biochem Biotechnol; 2016 Nov; 46(8):788-797. PubMed ID: 26829568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.
    Richter AW; Akerblom E
    Int Arch Allergy Appl Immunol; 1983; 70(2):124-31. PubMed ID: 6401699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
    Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
    J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
    Ozer I; Kelly G; Gu R; Li X; Zakharov N; Sirohi P; Nair SK; Collier JH; Hershfield MS; Hucknall AM; Chilkoti A
    Adv Sci (Weinh); 2022 Apr; 9(11):e2103672. PubMed ID: 35133079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
    Abuchowski A; Karp D; Davis FF
    J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity of the new quinolone antibacterial agent levofloxacin.
    Wagai N; Hattori H; Yamaguchi F; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):385-9. PubMed ID: 1622437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and biopharmaceutical properties of PEGylated uricase.
    Freitas Dda S; Spencer PJ; Vassão RC; Abrahão-Neto J
    Int J Pharm; 2010 Mar; 387(1-2):215-22. PubMed ID: 19969053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol.
    Savoca KV; Abuchowski A; van Es T; Davis FF; Palczuk NC
    Biochim Biophys Acta; 1979 May; 578(1):47-53. PubMed ID: 454671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antigenicity study of carboplatin in guinea pigs and mice].
    Kawano S; Kohmura H; Ohta S; Takahashi N
    J Toxicol Sci; 1988 Jul; 13 Suppl 2():1-21. PubMed ID: 3054128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.